| Literature DB >> 34223909 |
Marek Widera1, Alexander Wilhelm1, Sebastian Hoehl1, Christiane Pallas1, Niko Kohmer1, Timo Wolf2,3, Holger F Rabenau1, Victor M Corman4,5, Christian Drosten4,5, Maria J G T Vehreschild2,3, Udo Goetsch6, Rene Gottschalk6, Sandra Ciesek1,5,7.
Abstract
Whether monoclonal antibodies are able to neutralise SARS-CoV-2 variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralise authentic SARS-CoV-2 including variant B.1.1.7 (Alpha) but variants B.1.351 (Beta) and P.2 (Zeta) were resistant against bamlanivimab and partially to casirivimab.Entities:
Keywords: SARS-CoV-2; bamlanivimab; casirivimab; corona virus; imdevinab; monoclonal antibodies
Year: 2021 PMID: 34223909 DOI: 10.1093/infdis/jiab355
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226